ClinicalTrials.gg
Active, not recruitingNCT01946204SPARTANUpdated Sep 28, 2026Results posted

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

A Phase 3 interventional study of Apalutamide and Placebo in Prostatic Neoplasms, sponsored by Aragon Pharmaceuticals, Inc.. Active, not recruiting at 379 sites in 25 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,207
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
4th of 70
1,207 · median 81
Started
2013
with 2 others
Phase 3
16 of 70
2 open now
Primary completion
2017-05
later than 1 of 35 live
Registered
4th of 70
by date
Lead sponsor
9 of 70
Aragon Pharmaceuticals, Inc.

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2013, is one of 16 in phase 3, reaches primary completion later than 1 of the 35 other live ones, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.

Read the detailed description

This Phase 3 clinical trial is an essential step in the evaluation of an investigational medication to see if it may be useful in treating prostate cancer. The purpose of the SPARTAN study is to compare the safety and effectiveness of the investigational medication to placebo in delaying prostate cancer from spreading to other parts of the body. A placebo is a pill that looks like the investigational medication but does not contain any active medication, a dummy pill.

Phase 3 studies are performed after preliminary evidence suggesting effectiveness of the drug has been obtained in previous Phase 2 studies. These studies are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug.

Study participants will take the oral investigational medication daily. One cycle of study treatment lasts 4 weeks or 28 days. The number of cycles will depend on how you and your cancer respond to the study medication.

In order for the researchers to evaluate and compare the study results, there are two different study groups. Study participants will be randomly (like flipping a coin) assigned to one of these groups:

  • One group will receive their current treatment along with the investigational medication
  • One group will receive their current medications along with a placebo

The investigational medication will be given to 2 out of every 3 study participants. Neither you nor the study staff will know which group you are in. However, in case of a medical emergency, your study doctor can quickly find out which treatment group you are in.

All participants will continue to receive their current treatment along with either the investigational medication or a placebo. The selections will be random, and you may remain on investigational treatment until your disease worsens, or until significant side effects occur or you can no longer tolerate treatment.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Prostate neoplasms
  • Prostate cancer
  • Castration-resistant prostate cancer
  • Non-metastatic castration-resistant prostate cancer
  • ARN-509
  • Apalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features with high risk for development of , defined as prostate-specific antigen doubling time (PSADT) less than or equal to (\<=) 10 months. PSADT is calculated using at least 3 prostate-specific antigen (PSA) values obtained during continuous ADT (androgen deprivation therapy)
  • Castration-resistant prostate cancer demonstrated during continuous ADT, defined as 3 PSA rises, at least 1 week apart, with the last PSA greater than (>) 2 nanogram per milliliter (ng/mL)
  • Maintain castrate levels of testosterone within 4 weeks prior to randomization and throughout the study
  • Patients currently receiving bone loss prevention treatment with bone-sparing agents must be on stable doses for at least 4 weeks prior to randomization
  • Patients who received a first generation anti-androgen (for example, bicalutamide, flutamide, nilutamide) must have at least a 4-week prior to randomization AND must show continuing disease (PSA) progression (an increase in PSA) after washout
  • At least 4 weeks must have elapsed from the use of 5-alpha reductase inhibitors, estrogens, and any other anti-cancer therapy prior to randomization
  • At least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomization
  • Performance Status 0 or 1
  • Resolution of all acute toxic effects of prior therapy or surgical procedure to Grade \<= 1 or baseline prior to randomization
  • Adequate organ function according to protocol-defined criteria
  • Administration of growth factors or blood transfusions will not be allowed within 4 weeks of the hematology labs required to confirm eligibility

Exclusion criteria

Exclusion Criteria:

  • Presence of confirmed distant , including central nervous system and vertebral or meningeal involvement
  • Symptomatic local or regional disease requiring medical intervention
  • Prior treatment with second generation anti-androgens
  • Prior treatment with CYP17 inhibitors
  • Prior treatment with radiopharmaceutical agents, or any other agent for non-metastatic castration-resistant prostate cancer
  • Prior chemotherapy for prostate cancer except if administered in the /neoadjuvant setting
  • History of seizure or condition that may pre-dispose to seizure
  • Concurrent therapy with protocol-defined excluded medications
  • History or evidence of any of the following conditions: any prior (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization; severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events, or ventricular arrhythmias within 6 months prior to randomization; uncontrolled hypertension; gastrointestinal disorder affecting absorption; active infection; and, any other condition that, in the opinion of the investigator, would impair the patient's ability to comply with study procedures
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,207 participants (actual)

Study arms

  • Experimental
    Treatment Arm A: Apalutamide

    Drug: Apalutamide

  • Placebo comparator
    Treatment Arm B: Placebo

    Drug: Placebo

Interventions

  • 240 mg tablets administered by mouth on a continuous once daily dosing regimen

  • DrugPlacebo

    Matched placebo tablets administered by mouth on a continuous once daily dosing regimen

06

What researchers measure

Primary outcomes

  1. Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)

    MFS was defined as the time from randomization to the time of first evidence of BICR-confirmed bone or soft tissue distant metastasis or death due to any cause, whichever occurred first. The MFS data for participants without metastasis or death were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and computerized tomography \[CT\] or magnetic resonance imaging \[MRI\] of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study.

    Time frame: Up to approximately 43 Months

Secondary outcomes

  1. Time to Metastasis (TTM)

    Time to metastasis (TTM) was defined as the time from randomization to the time of the scan that showed first evidence of BICR-confirmed radiographically detected bone or soft tissue distant metastasis. The TTM data for participants without metastasis were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and CT or MRI of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study.

    Time frame: Up to approximately 43 Months

  2. Progression-free Survival (PFS)

    PFS defined as time from randomization to first documentation of BICR-confirmed radiographic progressive disease (PD) (development of distant/local/regional metastasis)/death due to any cause whichever occurred first. PFS data for participants without loco-regional disease were performed for US/ex-US regulatory purposes. Radiographic scans (bone scans and CT/MRI of chest,abdomen,pelvis) performed for detection of metastasis throughout study. PD based on RECIST v1.1; Subjects with one measurable lesion, At least 20% increase in sum of diameters of target lesions taking as reference smallest sum on study. In addition, sum must demonstrate an absolute increase of at least 5 millimeter(mm). Also, appearance of one/more new lesions was also considered PD. Subjects with non-measurable disease as per CT/MRI scans, unequivocal progression/appearance of one or more new lesions was considered PD. For new bone lesions detected on bone scans, second imaging (CT/MRI) was required to confirm PD.

    Time frame: Up to approximately 43 Months

  3. Time to Symptomatic Progression

    Time to symptomatic progression was defined as the time from randomization to documentation in the CRF of any of the following (whichever occurred earlier): a) development of a skeletal-related event (pathologic fracture, spinal cord compression, or need for surgical intervention or radiation therapy to the bone); b) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy; or c) development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy.

    Time frame: Up to approximately 43 Months

  4. Overall Survival

    Overall survival was defined as the time from randomization to the date of death due to any cause.

    Time frame: Up to approximately 43 months

  5. Time to Initiation of Cytotoxic Chemotherapy

    Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer.

    Time frame: Up to approximately 43 months

07

Results

Posted Jun 19, 2018
Limitations and caveats
These results are up to clinical cutoff (CCO) date (that is, 19 May 2017).

Participant flow

Participant flow — Overall Study
MilestonePlaceboApalutamide
Started401806
Treated398803
Completed00
Not completed401806
Withdrew: Death3859
Withdrew: Withdrawal by subject3750
Withdrew: Lost to follow-up37
Withdrew: Ongoing316687
Withdrew: Other73

Outcome measures

SecondaryTime to Metastasis (TTM)

Time to metastasis (TTM) was defined as the time from randomization to the time of the scan that showed first evidence of BICR-confirmed radiographically detected bone or soft tissue distant metastasis. The TTM data for participants without metastasis were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and CT or MRI of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study.

Time frame:
Up to approximately 43 Months
Reported as:
Median · Months
Time to Metastasis (TTM)
MonthsPlaceboApalutamide
US Regulatory16.59 (14.59 to 18.46)40.51 (NA to NA)
EX-US Regulatory15.70 (14.55 to 18.40)40.51 (31.15 to 40.51)
Statistical analysis
  • Placebo vs Apalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.271 · 95% CI 0.219 to 0.335
  • Placebo vs Apalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.279 · 95% CI 0.227 to 0.342
SecondaryProgression-free Survival (PFS)

PFS defined as time from randomization to first documentation of BICR-confirmed radiographic progressive disease (PD) (development of distant/local/regional metastasis)/death due to any cause whichever occurred first. PFS data for participants without loco-regional disease were performed for US/ex-US regulatory purposes. Radiographic scans (bone scans and CT/MRI of chest,abdomen,pelvis) performed for detection of metastasis throughout study. PD based on RECIST v1.1; Subjects with one measurable lesion, At least 20% increase in sum of diameters of target lesions taking as reference smallest sum on study. In addition, sum must demonstrate an absolute increase of at least 5 millimeter(mm). Also, appearance of one/more new lesions was also considered PD. Subjects with non-measurable disease as per CT/MRI scans, unequivocal progression/appearance of one or more new lesions was considered PD. For new bone lesions detected on bone scans, second imaging (CT/MRI) was required to confirm PD.

Time frame:
Up to approximately 43 Months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsPlaceboApalutamide
US Regulatory14.72 (14.49 to 18.37)40.51 (NA to NA)
EX-US Regulatory14.65 (11.27 to 17.97)40.51 (29.40 to 40.51)
Statistical analysis
  • Placebo vs Apalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.291 · 95% CI 0.238 to 0.356
  • Placebo vs Apalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.300 · 95% CI 0.247 to 0.364
SecondaryTime to Symptomatic Progression

Time to symptomatic progression was defined as the time from randomization to documentation in the CRF of any of the following (whichever occurred earlier): a) development of a skeletal-related event (pathologic fracture, spinal cord compression, or need for surgical intervention or radiation therapy to the bone); b) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy; or c) development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy.

Time frame:
Up to approximately 43 Months
Reported as:
Median · Months
Time to Symptomatic Progression
MonthsPlaceboApalutamide
Time to Symptomatic ProgressionNA (36.83 to NA)NA (NA to NA)
Statistical analysis
  • Placebo vs Apalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.447 · 95% CI 0.315 to 0.634
SecondaryOverall Survival

Overall survival was defined as the time from randomization to the date of death due to any cause.

Time frame:
Up to approximately 43 months
Reported as:
Median · Months
Overall Survival
MonthsPlaceboApalutamide
Overall Survival39.03 (39.03 to NA)NA (NA to NA)
SecondaryTime to Initiation of Cytotoxic Chemotherapy

Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer.

Time frame:
Up to approximately 43 months
Reported as:
Median · Months
Time to Initiation of Cytotoxic Chemotherapy
MonthsPlaceboApalutamide
Time to Initiation of Cytotoxic ChemotherapyNA (NA to NA)NA (NA to NA)
PrimaryMetastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)

MFS was defined as the time from randomization to the time of first evidence of BICR-confirmed bone or soft tissue distant metastasis or death due to any cause, whichever occurred first. The MFS data for participants without metastasis or death were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and computerized tomography \[CT\] or magnetic resonance imaging \[MRI\] of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study.

Time frame:
Up to approximately 43 Months
Reported as:
Median · Months
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)
MonthsPlaceboApalutamide
US Regulatory16.20 (14.59 to 18.40)40.51 (NA to NA)
Ex-US Regulatory15.70 (14.55 to 18.40)40.51 (29.70 to 40.51)
Statistical analysis
  • Placebo vs Apalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.280 · 95% CI 0.227 to 0.346
  • Placebo vs Apalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.297 · 95% CI 0.244 to 0.362

Adverse events

Collected over Up to approximately 43 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/398 (0.3%)92/398 (23.1%)329/398 (82.7%)
Apalutamide10/803 (1.2%)199/803 (24.8%)716/803 (89.2%)
Most frequent serious events
Showing 10 of 259
Most frequent serious events
EventPlaceboApalutamide
Urinary RetentionRenal and urinary disorders15/39810/803
HaematuriaRenal and urinary disorders8/39813/803
HydronephrosisRenal and urinary disorders8/3988/803
Urinary Tract InfectionInfections and infestations3/39810/803
PneumoniaInfections and infestations2/3989/803
Acute Kidney InjuryRenal and urinary disorders4/3986/803
Urinary Tract ObstructionRenal and urinary disorders4/3982/803
Atrial FibrillationCardiac disorders2/3987/803
SepsisInfections and infestations0/3987/803
Renal FailureRenal and urinary disorders3/3983/803
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPlaceboApalutamide
FatigueGeneral disorders84/398244/803
HypertensionVascular disorders77/398198/803
DiarrhoeaGastrointestinal disorders60/398159/803
NauseaGastrointestinal disorders63/398145/803
Weight DecreasedInvestigations25/398128/803
ArthralgiaMusculoskeletal and connective tissue disorders30/398128/803
FallInjury, poisoning and procedural complications35/398121/803
Back PainMusculoskeletal and connective tissue disorders59/398100/803
Hot FlushVascular disorders34/398113/803
ConstipationGastrointestinal disorders52/39887/803

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboApalutamideTotal
Mean74.1 ± 7.9273.7 ± 8.0773.9 ± 8.02
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApalutamideTotal
Female000
Male4018061207
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboApalutamideTotal
Hispanic or Latino51116
Not Hispanic or Latino338659997
Unknown or Not Reported58136194
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboApalutamideTotal
American Indian or Alaska Native044
Asian4793140
Native Hawaiian or Other Pacific Islander000
Black or African American204868
White276524800
More than one race011
Unknown or Not Reported58136194
Region of Enrollment
Region of Enrollment(Participants)PlaceboApalutamideTotal
Australia113041
Austria246
Belgium347
Canada216182
Czech Republic142034
Denmark71421
Finland5712
France213960
Germany203151
Hungary145
Israel7714
Italy122436
Japan213455
Netherlands11819
New Zealand268
Norway347
Poland62834
Romania5712
Russia112435
Slovakia61117
South Africa173552
Spain3695131
Sweden31013
Taiwan, Province Of China51419
United Kingdom386199
United States113224337
08

Study locations

379 sites
  • Birmingham, Alabama, United States
  • Anchorage, Alaska, United States
  • Chandler, Arizona, United States
  • Tucson, Arizona, United States
  • Duarte, California, United States
  • Fullerton, California, United States
  • Laguna Woods, California, United States
  • Los Angeles, California, United States
  • Orange, California, United States
  • Roseville, California, United States
  • Sacramento, California, United States
  • San Bernardino, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Santa Monica, California, United States
  • Sherman Oaks, California, United States
  • Stanford, California, United States
  • Tarzana, California, United States
  • Torrance, California, United States
  • Denver, Colorado, United States
  • Englewood, Colorado, United States
  • Glenwood Springs, Colorado, United States
  • Grand Junction, Colorado, United States
  • Washington D.C., District of Columbia, United States
  • Aventura, Florida, United States
  • Boca Raton, Florida, United States
  • Bradenton, Florida, United States
  • Daytona Beach, Florida, United States
  • Fort Myers, Florida, United States
  • Hialeah, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • New Port Richey, Florida, United States
  • Orlando, Florida, United States
  • Sarasota, Florida, United States
  • St. Petersburg, Florida, United States
  • Wellington, Florida, United States
  • Meridian, Idaho, United States
  • Chicago, Illinois, United States
  • Decatur, Illinois, United States
  • Maywood, Illinois, United States
  • Melrose Park, Illinois, United States
  • Carmel, Indiana, United States
  • Jeffersonville, Indiana, United States
  • Muncie, Indiana, United States
  • West Des Moines, Iowa, United States
  • Westwood, Kansas, United States
  • Wichita, Kansas, United States
  • Metairie, Louisiana, United States
  • New Orleans, Louisiana, United States
  • Annapolis, Maryland, United States
  • Baltimore, Maryland, United States
  • Rockville, Maryland, United States
  • Towson, Maryland, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Lansing, Michigan, United States
  • Minneapolis, Michigan, United States
  • Royal Oak, Michigan, United States
  • Duluth, Minnesota, United States
  • Bay Saint Louis, Mississippi, United States
  • Southaven, Mississippi, United States
  • Kansas City, Missouri, United States
  • Missoula, Montana, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Hooksett, New Hampshire, United States
  • Hackensack, New Jersey, United States
  • Lawrenceville, New Jersey, United States
  • Morristown, New Jersey, United States
  • Mount Laurel, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Voorhees Township, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Albany, New York, United States
  • Mineola, New York, United States
  • New York, New York, United States
  • Oneida, New York, United States
  • Poughkeepsie, New York, United States
  • Syracuse, New York, United States
  • The Bronx, New York, United States
  • Concord, North Carolina, United States
  • Greensboro, North Carolina, United States
  • Greenville, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Middleburg Heights, Ohio, United States
  • Middletown, Ohio, United States
  • Bend, Oregon, United States
  • Portland, Oregon, United States
  • Tualatin, Oregon, United States
  • Bala-Cynwyd, Pennsylvania, United States
  • Bryn Mawr, Pennsylvania, United States
  • Lancaster, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Warwick, Rhode Island, United States
  • Charleston, South Carolina, United States

Showing the first 100 of 379 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ni X, Sui J, Wang B, Wang H, Freedland SJ, Ye D, Zhu Y. Lower Testosterone Level and Metastases-Free Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With Novel Antiandrogens: A Post Hoc Analysis of SPARTAN and ARAMIS. J Urol. 2025 Jul;214(1):10-17. doi: 10.1097/JU.0000000000004545. Epub 2025 Mar 25. PubMed 40132221 ↗
  • Feng FY, Smith MR, Saad F, Mobadersany P, Tian SK, Yip SSF, Greshock J, Khan N, Yu MK, McCarthy S, Brookman-May SD, Bourla AB, Todorovic T, Yamashita R, Huang HC, Royce TJ, Showalter TN, Griffin J, Mitani A, Esteva A, Small EJ. Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2025 Jan;9:e2400653. doi: 10.1200/PO-24-00653. Epub 2025 Jan 31. PubMed 39889245 ↗
  • Roy S, Malone S, Wing K, Chowdhury S, Kishan AU, Sun Y, Wallis CJD, Mohamad O, Jia AY, Swami U, Zaorsky NG, Morgan SC, Ong M, Agarwal N, Spratt DE, Small EJ, Saad F. Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial. JAMA Netw Open. 2024 Oct 1;7(10):e2439434. doi: 10.1001/jamanetworkopen.2024.39434. PubMed 39405060 ↗
  • Karsh LI, Bevans KB, Saad F, Chung BH, Oudard S, Brookman-May SD, McCarthy SA, Smith MR, Chi KN, Small EJ, Agarwal N. Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. Future Oncol. 2024;20(35):2689-2698. doi: 10.1080/14796694.2024.2384257. Epub 2024 Aug 20. PubMed 39163505 ↗
  • Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. Br J Cancer. 2024 Jan;130(1):73-81. doi: 10.1038/s41416-023-02492-8. Epub 2023 Nov 11. PubMed 37951974 ↗
  • Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, Small EJ. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):156-161. doi: 10.1038/s41391-022-00592-9. Epub 2022 Oct 8. PubMed 36209239 ↗
  • Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison. Adv Ther. 2022 Jan;39(1):518-531. doi: 10.1007/s12325-021-01885-6. Epub 2021 Nov 19. PubMed 34797506 ↗
  • Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A, Smith A, Uemura H. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol. 2020 Sep 2;20(1):139. doi: 10.1186/s12894-020-00689-0. PubMed 32878613 ↗
  • Smith MR, Mehra M, Nair S, Lawson J, Small EJ. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2020 Apr;18(2):e180-e189. doi: 10.1016/j.clgc.2019.10.030. Epub 2019 Nov 6. PubMed 31980408 ↗
  • Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10. PubMed 30213449 ↗
  • Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. PubMed 29420164 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in May 2017, 43 months.

Results were first posted in Jun 2018, 1 year 1 month after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 43 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2013
First posted
Sep 19, 2013
StartActual
Oct 14, 2013
Primary completionActual
May 19, 2017
CompletionEst.
Dec 31, 2027
Results first posted
Jun 19, 2018
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01946204
Responsible party
Sponsor
First posted
Sep 19, 2013
Start date
Oct 14, 2013
Primary completion
May 19, 2017
Completion
Dec 31, 2027 (estimated)
Results posted
Jun 19, 2018
Last update
Sep 28, 2026

Study contacts

Aragon Pharmaceuticals, Inc. Clinical Trial
study director · Aragon Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion